.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Hepatic Metastases
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hepatic Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Calcium folinate pentahydrate Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Irinotecan Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Eloxatin Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Sonovue University Hospital, Tours | Phase 2 | B |
Ipilimumab Masonic Cancer Center, University of Minnesota | Phase 1/2 | CCC |
Nivolumab David Minor, MD | Phase 1/2 | CCC |
Same molecule, other indications
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →